APO Research
Talk to an analyst

APO RESEARCH · REPORT

FIC Drugs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global FIC Drugs Market Outlook and Growth Opportunities 2026

29 December 2025204 pages

Choose your research edition.

Industry ResearchFIC Drugs Industry Research Report 2026130 pages · $2,950 USDIndustry Growth & TrendsGlobal FIC Drugs Industry Growth and Trends Forecast to 2032116 pages · $3,450 USDMarket StructureGlobal FIC Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal FIC Drugs Market Outlook and Growth Opportunities 2026204 pages · $4,250 USDMarket Analysis & ForecastGlobal FIC Drugs Market Analysis and Forecast 2026-2032207 pages · $4,950 USD

Market perspective

The global FIC Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for FIC Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for FIC Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for FIC Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the FIC Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the FIC Drugs market include Agios, BMS, Boehringer Ingelheim, Dermavant Sciences, Genentech, Gilead, Immunocore, ImmunoGen and Mallinckrodt, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global FIC Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of FIC Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents FIC Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the FIC Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

FIC Drugs Segment by Company

Agios

BMS

Boehringer Ingelheim

Dermavant Sciences

Genentech

Gilead

Immunocore

ImmunoGen

Mallinckrodt

Marinus

Phathom

Polarean lmaging

Pfizer

Eli Lilly

Roche

Merck

Novartis

Johnson & Johnson

Sanofi

FIC Drugs Segment by Type

FIC Single-target Drugs

FIC Dual-target Drugs

FIC Drugs Segment by Application

Hospital

Clinic

Other

FIC Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global FIC Drugs status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions FIC Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify FIC Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze FIC Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global FIC Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of FIC Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of FIC Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the FIC Drugs market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global FIC Drugs industry.

Chapter 3: Detailed analysis of FIC Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of FIC Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of FIC Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. FIC Drugs Industry Trends Table 2. FIC Drugs Industry Drivers Table 3. FIC Drugs Industry Opportunities and Challenges Table 4. FIC Drugs Industry Restraints Table 5. Global FIC Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global FIC Drugs Revenue Share by Company (2021-2026) Table 7. Global FIC Drugs Sales Volume by Company (K Units) & (2021-2026) Table 8. Global FIC Drugs Sales Volume Share by Company (2021-2026) Table 9. Global FIC Drugs Average Price (US$/Unit) of Company (2021-2026) Table 10. Global FIC Drugs Company Ranking, (2024-2026) & (USD Million) Table 11. Global FIC Drugs Key Company Manufacturing Base & Headquarters Table 12. Global FIC Drugs Company, Product Type & Application Table 13. Global FIC Drugs Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global FIC Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of FIC Single-target Drugs Table 18. Significant Companies of FIC Dual-target Drugs Table 19. Global FIC Drugs Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global FIC Drugs Sales Volume by Type (2021-2026) & (K Units) Table 21. Global FIC Drugs Sales Volume by Type (2027-2032) & (K Units) Table 22. Global FIC Drugs Sales Volume Share by Type (2021-2026) Table 23. Global FIC Drugs Sales Volume Share by Type (2027-2032) Table 24. Global FIC Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global FIC Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global FIC Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global FIC Drugs Sales Value Share by Type (2021-2026) Table 28. Global FIC Drugs Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Hospital Table 30. Significant Companies of Clinic Table 31. Significant Companies of Other Table 32. Global FIC Drugs Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 33. Global FIC Drugs Sales Volume by Application (2021-2026) & (K Units) Table 34. Global FIC Drugs Sales Volume by Application (2027-2032) & (K Units) Table 35. Global FIC Drugs Sales Volume Share by Application (2021-2026) Table 36. Global FIC Drugs Sales Volume Share by Application (2027-2032) Table 37. Global FIC Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global FIC Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 39. Global FIC Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 40. Global FIC Drugs Sales Value Share by Application (2021-2026) Table 41. Global FIC Drugs Sales Value Share by Application (2027-2032) Table 42. Global FIC Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 43. Global FIC Drugs Sales by Region (2021-2026) & (K Units) Table 44. Global FIC Drugs Sales Market Share by Region (2021-2026) Table 45. Global FIC Drugs Sales by Region (2027-2032) & (K Units) Table 46. Global FIC Drugs Sales Market Share by Region (2027-2032) Table 47. Global FIC Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global FIC Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 49. Global FIC Drugs Sales Value Share by Region (2021-2026) Table 50. Global FIC Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 51. Global FIC Drugs Sales Value Share by Region (2027-2032) Table 52. Global FIC Drugs Market Average Price (US$/Unit) by Region (2021-2026) Table 53. Global FIC Drugs Market Average Price (US$/Unit) by Region (2027-2032) Table 54. Global FIC Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 55. Global FIC Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 56. Global FIC Drugs Sales by Country (2021-2026) & (K Units) Table 57. Global FIC Drugs Sales Market Share by Country (2021-2026) Table 58. Global FIC Drugs Sales by Country (2027-2032) & (K Units) Table 59. Global FIC Drugs Sales Market Share by Country (2027-2032) Table 60. Global FIC Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 61. Global FIC Drugs Sales Value Market Share by Country (2021-2026) Table 62. Global FIC Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 63. Global FIC Drugs Sales Value Market Share by Country (2027-2032) Table 64. Agios Company Information Table 65. Agios Business Overview Table 66. Agios FIC Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 67. Agios FIC Drugs Product Portfolio Table 68. Agios Recent Development Table 69. BMS Company Information Table 70. BMS Business Overview Table 71. BMS FIC Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 72. BMS FIC Drugs Product Portfolio Table 73. BMS Recent Development Table 74. Boehringer Ingelheim Company Information Table 75. Boehringer Ingelheim Business Overview Table 76. Boehringer Ingelheim FIC Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 77. Boehringer Ingelheim FIC Drugs Product Portfolio Table 78. Boehringer Ingelheim Recent Development Table 79. Dermavant Sciences Company Information Table 80. Dermavant Sciences Business Overview Table 81. Dermavant Sciences FIC Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 82. Dermavant Sciences FIC Drugs Product Portfolio Table 83. Dermavant Sciences Recent Development Table 84. Genentech Company Information Table 85. Genentech Business Overview Table 86. Genentech FIC Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 87. Genentech FIC Drugs Product Portfolio Table 88. Genentech Recent Development Table 89. Gilead Company Information Table 90. Gilead Business Overview Table 91. Gilead FIC Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. Gilead FIC Drugs Product Portfolio Table 93. Gilead Recent Development Table 94. Immunocore Company Information Table 95. Immunocore Business Overview Table 96. Immunocore FIC Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. Immunocore FIC Drugs Product Portfolio Table 98. Immunocore Recent Development Table 99. ImmunoGen Company Information Table 100. ImmunoGen Business Overview Table 101. ImmunoGen FIC Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 102. ImmunoGen FIC Drugs Product Portfolio Table 103. ImmunoGen Recent Development Table 104. Mallinckrodt Company Information Table 105. Mallinckrodt Business Overview Table 106. Mallinckrodt FIC Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 107. Mallinckrodt FIC Drugs Product Portfolio Table 108. Mallinckrodt Recent Development Table 109. Marinus Company Information Table 110. Marinus Business Overview Table 111. Marinus FIC Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 112. Marinus FIC Drugs Product Portfolio Table 113. Marinus Recent Development Table 114. Phathom Company Information Table 115. Phathom Business Overview Table 116. Phathom FIC Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 117. Phathom FIC Drugs Product Portfolio Table 118. Phathom Recent Development Table 119. Polarean lmaging Company Information Table 120. Polarean lmaging Business Overview Table 121. Polarean lmaging FIC Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 122. Polarean lmaging FIC Drugs Product Portfolio Table 123. Polarean lmaging Recent Development Table 124. Pfizer Company Information Table 125. Pfizer Business Overview Table 126. Pfizer FIC Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 127. Pfizer FIC Drugs Product Portfolio Table 128. Pfizer Recent Development Table 129. Eli Lilly Company Information Table 130. Eli Lilly Business Overview Table 131. Eli Lilly FIC Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 132. Eli Lilly FIC Drugs Product Portfolio Table 133. Eli Lilly Recent Development Table 134. Roche Company Information Table 135. Roche Business Overview Table 136. Roche FIC Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 137. Roche FIC Drugs Product Portfolio Table 138. Roche Recent Development Table 139. Merck Company Information Table 140. Merck Business Overview Table 141. Merck FIC Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 142. Merck FIC Drugs Product Portfolio Table 143. Merck Recent Development Table 144. Novartis Company Information Table 145. Novartis Business Overview Table 146. Novartis FIC Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 147. Novartis FIC Drugs Product Portfolio Table 148. Novartis Recent Development Table 149. Johnson & Johnson Company Information Table 150. Johnson & Johnson Business Overview Table 151. Johnson & Johnson FIC Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 152. Johnson & Johnson FIC Drugs Product Portfolio Table 153. Johnson & Johnson Recent Development Table 154. Sanofi Company Information Table 155. Sanofi Business Overview Table 156. Sanofi FIC Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 157. Sanofi FIC Drugs Product Portfolio Table 158. Sanofi Recent Development Table 159. Key Raw Materials Table 160. Raw Materials Key Suppliers Table 161. FIC Drugs Distributors List Table 162. FIC Drugs Customers List Table 163. Research Programs/Design for This Report Table 164. Authors List of This Report Table 165. Secondary Sources Table 166. Primary Sources List of Figures Figure 1. FIC Drugs Product Image Figure 2. Global FIC Drugs Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global FIC Drugs Sales Value (2021-2032) & (US$ Million) Figure 4. Global FIC Drugs Sales (2021-2032) & (K Units) Figure 5. Global FIC Drugs Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global FIC Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. FIC Single-target Drugs Image Figure 10. FIC Dual-target Drugs Image Figure 11. Global FIC Drugs Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global FIC Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global FIC Drugs Sales Volume Share by Type (2021-2032) Figure 14. Global FIC Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global FIC Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global FIC Drugs Sales Value Share by Type (2021-2032) Figure 17. Hospital Image Figure 18. Clinic Image Figure 19. Other Image Figure 20. Global FIC Drugs Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 21. Global FIC Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 22. Global FIC Drugs Sales Volume Share by Application (2021-2032) Figure 23. Global FIC Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global FIC Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 25. Global FIC Drugs Sales Value Share by Application (2021-2032) Figure 26. Global FIC Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 27. Global FIC Drugs Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 28. Global FIC Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 29. Global FIC Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 30. North America FIC Drugs Sales Value (2021-2032) & (US$ Million) Figure 31. North America FIC Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Europe FIC Drugs Sales Value (2021-2032) & (US$ Million) Figure 33. Europe FIC Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Asia-Pacific FIC Drugs Sales Value (2021-2032) & (US$ Million) Figure 35. Asia-Pacific FIC Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 36. South America FIC Drugs Sales Value (2021-2032) & (US$ Million) Figure 37. South America FIC Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Middle East & Africa FIC Drugs Sales Value (2021-2032) & (US$ Million) Figure 39. Middle East & Africa FIC Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 40. USA FIC Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. USA FIC Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. USA FIC Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Canada FIC Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Canada FIC Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Canada FIC Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Mexico FIC Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Mexico FIC Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Mexico FIC Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Germany FIC Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Germany FIC Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Germany FIC Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. France FIC Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. France FIC Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. France FIC Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. U.K. FIC Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. U.K. FIC Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. U.K. FIC Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Italy FIC Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Italy FIC Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Italy FIC Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Spain FIC Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Spain FIC Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Spain FIC Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Russia FIC Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Russia FIC Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Russia FIC Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Netherlands FIC Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Netherlands FIC Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Netherlands FIC Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Nordic Countries FIC Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Nordic Countries FIC Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Nordic Countries FIC Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. China FIC Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. China FIC Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. China FIC Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Japan FIC Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Japan FIC Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Japan FIC Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. South Korea FIC Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. South Korea FIC Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. South Korea FIC Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. India FIC Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. India FIC Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. India FIC Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Australia FIC Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Australia FIC Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Australia FIC Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Southeast Asia FIC Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Southeast Asia FIC Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Southeast Asia FIC Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Brazil FIC Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Brazil FIC Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Brazil FIC Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Argentina FIC Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Argentina FIC Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Argentina FIC Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Chile FIC Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Chile FIC Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Chile FIC Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Colombia FIC Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Colombia FIC Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Colombia FIC Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Peru FIC Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Peru FIC Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Peru FIC Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Saudi Arabia FIC Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Saudi Arabia FIC Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Saudi Arabia FIC Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Israel FIC Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Israel Arabia FIC Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Israel Arabia FIC Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. UAE FIC Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. UAE FIC Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. UAE FIC Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Turkey FIC Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Turkey FIC Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Turkey FIC Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Iran FIC Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Iran FIC Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Iran FIC Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Egypt FIC Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Egypt FIC Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Egypt FIC Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. FIC Drugs Value Chain Figure 125. Manufacturing Cost Structure Figure 126. FIC Drugs Sales Mode & Process Figure 127. Direct Comparison with Distribution Share Figure 128. Distributors Profiles Figure 129. Years Considered Figure 130. Research Process Figure 131. Key Executives Interviewed

Scope & coverage.

Types
  • FIC Single-target Drugs
  • FIC Dual-target Drugs
Applications
  • Hospital
  • Clinic
  • Other
Companies covered
  • Agios
  • BMS
  • Boehringer Ingelheim
  • Dermavant Sciences
  • Genentech
  • Gilead
  • Immunocore
  • ImmunoGen
  • Mallinckrodt
  • Marinus
  • Phathom
  • Polarean lmaging
  • Pfizer
  • Eli Lilly
  • Roche
  • Merck
  • Novartis
  • Johnson & Johnson
  • Sanofi

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global FIC Drugs Sales Value (2021-2032)
  4. 1.2.2 Global FIC Drugs Sales Volume (2021-2032)
  5. 1.2.3 Global FIC Drugs Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 FIC Drugs Market Dynamics
  1. 2.1 FIC Drugs Industry Trends
  2. 2.2 FIC Drugs Industry Drivers
  3. 2.3 FIC Drugs Industry Opportunities and Challenges
  4. 2.4 FIC Drugs Industry Restraints
3 FIC Drugs Market by Company
  1. 3.1 Global FIC Drugs Company Revenue Ranking in 2025
  2. 3.2 Global FIC Drugs Revenue by Company (2021-2026)
  3. 3.3 Global FIC Drugs Sales Volume by Company (2021-2026)
  4. 3.4 Global FIC Drugs Average Price by Company (2021-2026)
  5. 3.5 Global FIC Drugs Company Ranking (2024-2026)
  6. 3.6 Global FIC Drugs Company Manufacturing Base and Headquarters
  7. 3.7 Global FIC Drugs Company Product Type and Application
  8. 3.8 Global FIC Drugs Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global FIC Drugs Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 FIC Drugs Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 FIC Drugs Market by Type
  1. 4.1 FIC Drugs Type Introduction
  2. 4.1.1 FIC Single-target Drugs
  3. 4.1.2 FIC Dual-target Drugs
  4. 4.2 Global FIC Drugs Sales Volume by Type
  5. 4.2.1 Global FIC Drugs Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global FIC Drugs Sales Volume by Type (2021-2032)
  7. 4.2.3 Global FIC Drugs Sales Volume Share by Type (2021-2032)
  8. 4.3 Global FIC Drugs Sales Value by Type
  9. 4.3.1 Global FIC Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global FIC Drugs Sales Value by Type (2021-2032)
  11. 4.3.3 Global FIC Drugs Sales Value Share by Type (2021-2032)
5 FIC Drugs Market by Application
  1. 5.1 FIC Drugs Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Other
  5. 5.2 Global FIC Drugs Sales Volume by Application
  6. 5.2.1 Global FIC Drugs Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global FIC Drugs Sales Volume by Application (2021-2032)
  8. 5.2.3 Global FIC Drugs Sales Volume Share by Application (2021-2032)
  9. 5.3 Global FIC Drugs Sales Value by Application
  10. 5.3.1 Global FIC Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global FIC Drugs Sales Value by Application (2021-2032)
  12. 5.3.3 Global FIC Drugs Sales Value Share by Application (2021-2032)
6 FIC Drugs Regional Sales and Value Analysis
  1. 6.1 Global FIC Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global FIC Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global FIC Drugs Sales by Region: 2021-2026
  4. 6.2.2 Global FIC Drugs Sales by Region (2027-2032)
  5. 6.3 Global FIC Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global FIC Drugs Sales Value by Region (2021-2032)
  7. 6.4.1 Global FIC Drugs Sales Value by Region: 2021-2026
  8. 6.4.2 Global FIC Drugs Sales Value by Region (2027-2032)
  9. 6.5 Global FIC Drugs Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America FIC Drugs Sales Value (2021-2032)
  12. 6.6.2 North America FIC Drugs Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe FIC Drugs Sales Value (2021-2032)
  15. 6.7.2 Europe FIC Drugs Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific FIC Drugs Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific FIC Drugs Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America FIC Drugs Sales Value (2021-2032)
  21. 6.9.2 South America FIC Drugs Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa FIC Drugs Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa FIC Drugs Sales Value Share by Country, 2025 VS 2032
7 FIC Drugs Country-level Sales and Value Analysis
  1. 7.1 Global FIC Drugs Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global FIC Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global FIC Drugs Sales by Country (2021-2032)
  4. 7.3.1 Global FIC Drugs Sales by Country (2021-2026)
  5. 7.3.2 Global FIC Drugs Sales by Country (2027-2032)
  6. 7.4 Global FIC Drugs Sales Value by Country (2021-2032)
  7. 7.4.1 Global FIC Drugs Sales Value by Country (2021-2026)
  8. 7.4.2 Global FIC Drugs Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA FIC Drugs Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA FIC Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA FIC Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada FIC Drugs Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada FIC Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada FIC Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico FIC Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico FIC Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico FIC Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany FIC Drugs Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany FIC Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany FIC Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France FIC Drugs Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France FIC Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France FIC Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. FIC Drugs Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. FIC Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. FIC Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy FIC Drugs Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy FIC Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy FIC Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain FIC Drugs Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain FIC Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain FIC Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia FIC Drugs Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia FIC Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia FIC Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands FIC Drugs Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands FIC Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands FIC Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries FIC Drugs Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries FIC Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries FIC Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China FIC Drugs Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China FIC Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China FIC Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan FIC Drugs Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan FIC Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan FIC Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea FIC Drugs Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea FIC Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea FIC Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India FIC Drugs Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India FIC Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India FIC Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia FIC Drugs Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia FIC Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia FIC Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia FIC Drugs Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia FIC Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia FIC Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil FIC Drugs Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil FIC Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil FIC Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina FIC Drugs Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina FIC Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina FIC Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile FIC Drugs Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile FIC Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile FIC Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia FIC Drugs Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia FIC Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia FIC Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru FIC Drugs Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru FIC Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru FIC Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia FIC Drugs Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia FIC Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia FIC Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel FIC Drugs Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel FIC Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel FIC Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE FIC Drugs Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE FIC Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE FIC Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey FIC Drugs Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey FIC Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey FIC Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran FIC Drugs Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran FIC Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran FIC Drugs Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt FIC Drugs Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt FIC Drugs Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt FIC Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Agios
  2. 8.1.1 Agios Company Information
  3. 8.1.2 Agios Business Overview
  4. 8.1.3 Agios FIC Drugs Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Agios FIC Drugs Product Portfolio
  6. 8.1.5 Agios Recent Developments
  7. 8.2 BMS
  8. 8.2.1 BMS Company Information
  9. 8.2.2 BMS Business Overview
  10. 8.2.3 BMS FIC Drugs Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 BMS FIC Drugs Product Portfolio
  12. 8.2.5 BMS Recent Developments
  13. 8.3 Boehringer Ingelheim
  14. 8.3.1 Boehringer Ingelheim Company Information
  15. 8.3.2 Boehringer Ingelheim Business Overview
  16. 8.3.3 Boehringer Ingelheim FIC Drugs Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Boehringer Ingelheim FIC Drugs Product Portfolio
  18. 8.3.5 Boehringer Ingelheim Recent Developments
  19. 8.4 Dermavant Sciences
  20. 8.4.1 Dermavant Sciences Company Information
  21. 8.4.2 Dermavant Sciences Business Overview
  22. 8.4.3 Dermavant Sciences FIC Drugs Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Dermavant Sciences FIC Drugs Product Portfolio
  24. 8.4.5 Dermavant Sciences Recent Developments
  25. 8.5 Genentech
  26. 8.5.1 Genentech Company Information
  27. 8.5.2 Genentech Business Overview
  28. 8.5.3 Genentech FIC Drugs Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Genentech FIC Drugs Product Portfolio
  30. 8.5.5 Genentech Recent Developments
  31. 8.6 Gilead
  32. 8.6.1 Gilead Company Information
  33. 8.6.2 Gilead Business Overview
  34. 8.6.3 Gilead FIC Drugs Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Gilead FIC Drugs Product Portfolio
  36. 8.6.5 Gilead Recent Developments
  37. 8.7 Immunocore
  38. 8.7.1 Immunocore Company Information
  39. 8.7.2 Immunocore Business Overview
  40. 8.7.3 Immunocore FIC Drugs Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Immunocore FIC Drugs Product Portfolio
  42. 8.7.5 Immunocore Recent Developments
  43. 8.8 ImmunoGen
  44. 8.8.1 ImmunoGen Company Information
  45. 8.8.2 ImmunoGen Business Overview
  46. 8.8.3 ImmunoGen FIC Drugs Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 ImmunoGen FIC Drugs Product Portfolio
  48. 8.8.5 ImmunoGen Recent Developments
  49. 8.9 Mallinckrodt
  50. 8.9.1 Mallinckrodt Company Information
  51. 8.9.2 Mallinckrodt Business Overview
  52. 8.9.3 Mallinckrodt FIC Drugs Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Mallinckrodt FIC Drugs Product Portfolio
  54. 8.9.5 Mallinckrodt Recent Developments
  55. 8.10 Marinus
  56. 8.10.1 Marinus Company Information
  57. 8.10.2 Marinus Business Overview
  58. 8.10.3 Marinus FIC Drugs Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Marinus FIC Drugs Product Portfolio
  60. 8.10.5 Marinus Recent Developments
  61. 8.11 Phathom
  62. 8.11.1 Phathom Company Information
  63. 8.11.2 Phathom Business Overview
  64. 8.11.3 Phathom FIC Drugs Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Phathom FIC Drugs Product Portfolio
  66. 8.11.5 Phathom Recent Developments
  67. 8.12 Polarean lmaging
  68. 8.12.1 Polarean lmaging Company Information
  69. 8.12.2 Polarean lmaging Business Overview
  70. 8.12.3 Polarean lmaging FIC Drugs Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Polarean lmaging FIC Drugs Product Portfolio
  72. 8.12.5 Polarean lmaging Recent Developments
  73. 8.13 Pfizer
  74. 8.13.1 Pfizer Company Information
  75. 8.13.2 Pfizer Business Overview
  76. 8.13.3 Pfizer FIC Drugs Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Pfizer FIC Drugs Product Portfolio
  78. 8.13.5 Pfizer Recent Developments
  79. 8.14 Eli Lilly
  80. 8.14.1 Eli Lilly Company Information
  81. 8.14.2 Eli Lilly Business Overview
  82. 8.14.3 Eli Lilly FIC Drugs Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Eli Lilly FIC Drugs Product Portfolio
  84. 8.14.5 Eli Lilly Recent Developments
  85. 8.15 Roche
  86. 8.15.1 Roche Company Information
  87. 8.15.2 Roche Business Overview
  88. 8.15.3 Roche FIC Drugs Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Roche FIC Drugs Product Portfolio
  90. 8.15.5 Roche Recent Developments
  91. 8.16 Merck
  92. 8.16.1 Merck Company Information
  93. 8.16.2 Merck Business Overview
  94. 8.16.3 Merck FIC Drugs Sales, Value and Gross Margin (2021-2026)
  95. 8.16.4 Merck FIC Drugs Product Portfolio
  96. 8.16.5 Merck Recent Developments
  97. 8.17 Novartis
  98. 8.17.1 Novartis Company Information
  99. 8.17.2 Novartis Business Overview
  100. 8.17.3 Novartis FIC Drugs Sales, Value and Gross Margin (2021-2026)
  101. 8.17.4 Novartis FIC Drugs Product Portfolio
  102. 8.17.5 Novartis Recent Developments
  103. 8.18 Johnson & Johnson
  104. 8.18.1 Johnson & Johnson Company Information
  105. 8.18.2 Johnson & Johnson Business Overview
  106. 8.18.3 Johnson & Johnson FIC Drugs Sales, Value and Gross Margin (2021-2026)
  107. 8.18.4 Johnson & Johnson FIC Drugs Product Portfolio
  108. 8.18.5 Johnson & Johnson Recent Developments
  109. 8.19 Sanofi
  110. 8.19.1 Sanofi Company Information
  111. 8.19.2 Sanofi Business Overview
  112. 8.19.3 Sanofi FIC Drugs Sales, Value and Gross Margin (2021-2026)
  113. 8.19.4 Sanofi FIC Drugs Product Portfolio
  114. 8.19.5 Sanofi Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 FIC Drugs Value Chain Analysis
  2. 9.1.1 FIC Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 FIC Drugs Sales Mode & Process
  6. 9.2 FIC Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 FIC Drugs Distributors
  9. 9.2.3 FIC Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst